

GlycoMimetics to Report Third Quarter 2019 Financial Results on November 7, 2019

October 31, 2019

ROCKVILLE, Md.--(BUSINESS WIRE)--Oct. 31, 2019-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to report its third-quarter 2019 financial results on Thursday, November 7, 2019, at 8:30 a.m. ET.

The dial-in number for the conference call is (844) 413-7154 (U.S. and Canada) or (216) 562-0466 (international) and entering passcode 9845948. To access the live audio webcast, or the subsequent archived recording, visit the "Investors - Events & Presentations" section of the GlycoMimetics website at <u>www.glycomimetics.com</u>. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' wholly-owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005720/en/

Source: GlycoMimetics, Inc.

Investor Contact: Shari Annes Phone: 650-888-0902 Email: <u>sannes@annesassociates.com</u>

Media Contact: Jamie Lacey-Moreira Phone: 410-299-3310 Email: jamielacey@presscommpr.com